FG
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study | PloS one | 2022 | 65 | 46 | |||
Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease | Open Heart | 2021 | 192 | 118 | |||
Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy | JHEP Reports : Innovation in Hepatology | 2021 | 246 | 105 | |||
Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode | Swiss medical weekly | 2021 | 244 | 90 | |||
Emerging Concepts and Applied Machine Learning Research in Patients with Drug-Induced Repolarization Disorders | Studies in Health Technology and Informatics | 2020 | 421 | 128 | |||
Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients | Liver International | 2020 | 311 | 197 | |||
Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting | Clinical Infectious Diseases | 2019 | 367 | 269 | |||
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis | Journal of Viral Hepatitis | 2019 | 398 | 1 | |||
Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America | Journal of Tropical Medicine | 2018 | 688 | 251 | |||
Blood-borne and sexually transmitted infections: a cross-sectional study in a Swiss prison | BMC Infectious Diseases | 2018 | 318 | 129 | |||
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine | The Pharmacogenomics Journal | 2018 | 593 | 210 | |||
Health technology assessment: a framework for economic evaluations in policy guidance and medical management | 2017 | 417 | 7 | ||||
Health utility indexes in patients with acute coronary syndromes | Open heart | 2016 | 523 | 251 | |||
Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay | PloS one | 2016 | 822 | 330 | |||
Early specialized care after a first unprovoked epileptic seizure | Journal of neurology | 2016 | 622 | 2 | |||
Drug Pricing Evolution in Hepatitis C | PloS one | 2016 | 1,323 | 587 | |||
Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis | PloS one | 2015 | 474 | 215 | |||
Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chronique | Revue médicale suisse | 2015 | 498 | 1 | |||
Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis | The Lancet. Psychiatry | 2014 | 487 | 0 | |||
Patented drug extension strategies on healthcare spending: a cost-evaluation analysis | PLoS medicine | 2013 | 697 | 329 | |||
Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study | The American journal of psychiatry | 2013 | 640 | 1 | |||
Enseignement de recommandations pour la pratique: la prescription médicale au cabinet | Revue médicale suisse | 2013 | 391 | 136 | |||
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection | Journal of viral hepatitis | 2012 | 622 | 0 | |||
Sélection d'un médicament dans une classe thérapeutique donnée : l'exemple des «inhibiteurs de l'HMG-CoA réductase» | Revue médicale suisse | 2005 | 353 | 0 | |||
Rofecoxib interaction with oral anticoagulant acenocoumarol | European journal of clinical pharmacology | 2003 | 451 | 206 |